AZN Kewajiban utang agregat AstraZeneca

AstraZeneca PLC (AZN) relies on a strong portfolio of targeted therapies for rare pathologies and oncology. GURU.Markets analytics provide the aggregate debt structure, where the 33.12 indicator expresses the state of the metric. Leadership in molecular biology is supported by massive R&D expenditures, while current growth is driven by new blockbusters and promising early-stage pipeline developments.

Gunggung utang perusahaan: AstraZeneca AB (AZN) kanggo 04.07.2022 - 27.10.2026

Rincian analitis lan laporan data perusahaan AstraZeneca (AZN)

- rega lan prakiraan konsensus rega:

Rega saham AstraZeneca Corp.|AZN - Bagan rega target

- data kapitalisasi pasar:

Nilai pasar AstraZeneca AB|AZN - Nilai Total Perusahaan

- data kapitalisasi buku:

Nilai Akuntansi saben Saham AstraZeneca|AZN - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku astrazeneca.com|AZN - Gunggung Aset Perusahaan

- data utang lan likuiditas:

Rasio Kabeh Utang marang Dana Pribadi AstraZeneca PLC|AZN - Utang jangka dawa marang modal|Rasio tanggungan utang jangka cendhak marang modal AstraZeneca Plc|AZN - Utang perusahaan|Utang-utang marang nilai buku AstraZeneca AB

Pambiji fundamental perusahaan:AstraZeneca Corp. AZN

The company's debts reflect the aggregate of its credit obligations, determining the business's resilience to falling demand and the cost of servicing borrowings. The balance between risk minimization and aggressive expansion allows investors to assess the issuer's financial flexibility. By analyzing the volume of debt obligations, one can judge the capital development strategy. In AstraZeneca PLC (AZN), this is evidenced by a prudent acquisition policy and scientific transformation. Effective management utilizes debt capital to drive the long-term growth of the drug pipeline.

Pesaing AstraZeneca PLC